(Sharecast News) - US consumer health and drugs giant Johnson&Johnson has launched the last phase of clinical trials for its Covid-19 vaccine.
The vaccine candidate, JNJ-78436735, which is being developed by its subsidiary, Janssen Pharmaceutical, will now be tested on as many as 60,000 adults, which include a "significant representation" of volunteers aged 60 and over.
"With our vaccine candidate now in our global Phase 3 trial, we are one step closer to finding a solution for COVID-19," said Mathai Mammen, global head of Research & Development at Janssen.
"We used a highly scientific and evidence-based approach to select this vaccine candidate."
Start of the trial follows the successful completion of a phase 1/2a trial which determined the vaccine was safe and generated an immune response.
The aims of the phase three double-blind, placebo -controlled trial are to determine the safety and efficacy of a single dose of the drug.
As of 1218 BST, shares of Johnson&Johnson were advancing 2.48% to $147.79.
By Huw JonesLONDON, May 6 (Reuters) - Britain's financial watchdog has imposed its first fine in relation to an international sham trading scheme, known as "cum-ex", with potentially more to come, it said on Thursday.The Financial Conduct Authorit...